| Literature DB >> 29867131 |
Kae Yi Tan1, Nget Hong Tan1, Choo Hock Tan2.
Abstract
The easternEntities:
Mesh:
Substances:
Year: 2018 PMID: 29867131 PMCID: PMC5986800 DOI: 10.1038/s41598-018-25955-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1SDS-PAGE and proteomes of Daboia siamensis venoms. (a) D. siamensis and lyophilized venoms (top) and protein separation of Ds-Guangxi and Ds-Taiwan venoms on 15% SDS-PAGE under reducing conditions (bottom). (b) Venom proteome of Ds-Guangxi. (c) Venom proteome of Ds-Taiwan. The number of proteoforms of each protein family is in parentheses. Abbreviations: Ds-Guangxi: D. siamensis of Guangxi (mainland); Ds-Taiwan, D. siamensis of Taiwan (island); KSPI, Kunitz-type serine protease inhibitor; PLA2, phospholipase A2; Snaclec, snake venom C-type lectin/lectin-like protein; SVSP, snake venom serine protease; SVMP, snake venom metalloproteinase; LAAO, L-amino acid oxidase; svVEGF, snake venom vascular endothelial growth factor; svNGF, snake venom nerve growth factor; 5′NUC, 5′-nucleotidase; CRiSP, cysteine-rich secretory protein; PDE, phosphodiesterase. Note: SDS-PAGE of Ds-Guangxi and Ds-Taiwan venoms were cropped from the same gel for display purpose. The full-length gel is provided in the Supplementary Information File S1.
Proteomes of Daboia siamensis venoms from Guangxi and Taiwan profiled using nano-ESI-LCMS/MS.
| Protein Name | Database Accession | Species | ||||
|---|---|---|---|---|---|---|
| % | Proteoform | % | Proteoform | |||
|
|
|
| ||||
| Kunitz-type serine protease inhibitor C1 | A8Y7N4 | — | — | 12.18 | 1 | |
| Kunitz-type serine protease inhibitor C4 | A8Y7N7 | — | — | 3.51 | 2 | |
| Kunitz-type serine protease inhibitor B4 | A8Y7P4 | 6.53 | 1 | 3.43 | 3 | |
| Kunitz-type serine protease inhibitor B5 | A8Y7P5 | 4.91 | 2 | — | — | |
| Kunitz-type serine protease inhibitor B6 | A8Y7P6 | — | — | 1.77 | 4 | |
| Kunitz-type serine protease inhibitor 2 | P00990 | 11.72 | 3 | 7.31 | 5 | |
|
|
|
| ||||
| Acidic phospholipase A2 RV-7 | P31100 | — | — | 10.87 | 1 | |
| Basic phospholipase A2 RV-4 | Q02471 | — | — | 13.61 | 2 | |
| Acidic phospholipase A2 daboiatoxin A chain | Q7T2R1 | 5.30 | 1 | — | — | |
| Acidic phospholipase A2 daboiatoxin B chain | Q7T3T5 | 4.29 | 2 | — | — | |
| Basic phospholipase A2 DsM-b1 | A8CG82 | 2.38 | 3 | — | — | |
| Acidic phospholipase A2 DsM-a2 | A8CG78 | 4.21 | 4 | — | — | |
| Basic phospholipase A2 Drk-b1 | A8CG89 | 5.05 | 5 | — | — | |
| phospholipase A2-I | Q7ZZQ1 | 0.96 | 6 | — | — | |
|
|
|
| ||||
| Snaclec dabocetin subunit alpha | Q38L02 | 1.35 | 1 | — | — | |
| Snaclec A12 | B4XSY7 | 0.64 | 2 | — | — | |
| C-type lectin A12 | Unigene30367_DrSL* | 0.28 | 3 | — | — | |
| Snaclec 7 | Q4PRC6 | 2.93 | 4 | — | — | |
| Snaclec 5 | Q4PRC8 | 1.02 | 5 | — | — | |
| Snaclec 4 | Q4PRC9 | 2.01 | 6 | 1.43 | 1 | |
| Snaclec 3 | Q4PRD0 | 1.48 | 7 | 1.03 | 2 | |
| P31 alpha subunit | K9JBU9 | 0.48 | 8 | — | — | |
| P68 alpha subunit | K9JBV0 | 5.86 | 9 | 5.95 | 3 | |
| Snaclec coagulation factor X-activating enzyme light chain 1 | Q4PRD1 | — | — | 4.77 | 4 | |
| Snaclec coagulation factor X-activating enzyme light chain 2 | Q4PRD2 | 0.84 | 10 | 2.07 | 5 | |
| Factor X activator light chain 2 | K9JDJ1 | — | — | 1.28 | 6 | |
|
|
|
| ||||
| Alpha-fibrinogenase-like | E5L0E3 | 0.77 | 1 | 1.01 | 1 | |
| Beta-fibrinogenase | E0Y419 | 1.57 | 2 | 0.74 | 2 | |
| Beta-fibrinogenase-like | E5L0E4 | 2.50 | 3 | — | — | |
| serine beta-fibrinogenase-like protein | CL2958.contig11_DrSL* | 0.71 | 4 | 2.38 | 3 | |
| Factor V activator RVV-V gamma | P18965 | 2.79 | 5 | 8.11 | 4 | |
| Vipera russelli proteinase RVV-V homolog 2 | P86531 | 0.59 | 6 | — | — | |
| RVV-V gamma-like protein | CL31.contig2_Nn* | 1.14 | 7 | 2.19 | 5 | |
| Venom serine proteinase-like protein 2 | Q9PT40 | 0.30 | 8 | — | — | |
| Serine protease VLSP-1 | CL2958.contig6_DrSL* | 3.25 | 9 | 3.07 | 6 | |
|
|
|
| ||||
| Zinc metalloproteinase-disintegrin-like daborhagin-K | B8K1W0 | 4.44 | 1 | — | — | |
| Zinc metalloproteinase-disintegrin-like VLAIP-A | Q4VM08 | 0.36 | 2 | 1.34 | 1 | |
| Zinc metalloproteinase-disintegrin VLAIP-A | CL3662.contig2_DrSL* | 1.02 | 3 | 1.62 | 2 | |
| Zinc metalloproteinase-disintegrin VLAIP-A | Unigene31385_Nn* | 0.83 | 4 | 0.44 | 3 | |
| Coagulation factor X-activating enzyme heavy chain | Q7LZ61 | — | — | 2.45 | 4 | |
| factor X activator heavy chain | K9JAW0 | 1.03 | 5 | — | — | |
| factor X activator heavy chain | Unigene32626_DrSL* | 1.25 | 6 | — | — | |
|
|
| — | — | |||
| L-amino-acid oxidase | G8XQX1 | 1.29 | 1 | — | — | |
| L-amino-acid oxidase | P0C2D7 | 1.84 | 2 | — | — | |
| L-amino-acid oxidase | P81382 | 0.35 | 3 | — | — | |
| L-amino-acid oxidase | Q4F867 | 2.47 | 4 | — | — | |
|
|
|
| ||||
| Snake venom vascular endothelial growth factor toxin VR-1 | P0DL42 | 4.79 | 1 | 4.84 | 1 | |
|
|
|
| ||||
| Venom nerve growth factor | P30894 | 2.11 | 1 | 2.13 | 1 | |
|
|
| — | — | |||
| Snake venom 5′-nucleotidase | F8S0Z7 | 0.16 | 1 | — | — | |
| 5′-nucleotidase | U3T7C6 | 0.17 | 2 | — | — | |
| Snake venom 5′-nucleotidase | CL3322.contig1_DrSL* | 0.49 | 3 | — | — | |
|
|
| — | — | |||
| Cysteine-rich venom protein ablomin | Q8JI40 | 0.95 | 1 | — | — | |
|
|
|
|
|
| ||
| phosphodiesterase 1 | CL3655.contig2_DrSL* | 0.25 | 1 | 0.31 | 1 | |
|
|
|
| ||||
| Xaa-Pro aminopeptidase 2 | A0A0B8RNS9 | 0.20 | 1 | 0.13 | 1 | |
| Xaa-Pro aminopeptidase 2-like | Unigene32033_DrSL* | 0.15 | 2 | 0.02 | 2 | |
* indicate venom protein identified based on tryptic peptides matched to sequence from in-house transcripts database. Mass spectrometric data and peptide sequences are available in Supplementary Information Files S2A and B.
D. russelii, Daboia russelii; D. siamensis, Daboia siamensis; M. lebetina, Macrovipera lebetina; N. naja, Naja naja; Vipera berus berus, V. berus berus; C. rhodostoma, Calloselasma rhodostoma; C. adamanteus, Crotalus adamanteus; O. okinavensis, Ovophis okinavensis; G. blomhoffii, Gloydius blomhoffii; B. irregularis, Boiga irregularis.
Protein concentrations of the four antivenoms used.
| Antivenom | Protein concentration (mg/ml) |
|---|---|
| 19.3 ± 0.5 | |
| 40.8 ± 0.3 | |
| 168.5 ± 0.7 | |
| 181.1 ± 6.4 |
Figure 2Immunological binding activity of antivenoms (DsMAV-Taiwan, DsMAV-Thai, DaMAV, GbMAV and a 1:1 mixture of DaMAV:GbMAV) toward the venom antigens of Daboia siamensis from Guangxi and Taiwan.
Procoagulant effect of Daboia siamensis venoms sourced from Guangxi and Taiwan and its neutralization by antivenoms.
| MCDa (µg/ml) | Challenge dose (2MCD) (µg/ml) | DsMAV-Taiwan | GbMAV | DaMAV | ||||
|---|---|---|---|---|---|---|---|---|
| EDb (µl, mg/ml) | Normalized ED, n-EDc (mg/g) | EDb (µl, mg/ml) | Normalized ED, n-EDc (mg/g) | EDb (µl, mg/ml) | Normalized ED, n-EDc (mg/g) | |||
| Guangxi | 0.23 ± 0.06 | 0.46 | 0.044 ± 0.002, | 105.2 | 1.183 ± 0.017, | 0.4 | >10, | <0.05 |
| Taiwan | 0.15 ± 0.04 | 0.30 | 0.036 ± 0.003, | 73.1 | 2.633 ± 0.088, | 0.1 | >10, | <0.05 |
MCD: Minimal clotting dose; ED: Effective dose.
aMinimal clotting dose was defined as the dose of venom (µg/ml) required to cause clotting in 5 minutes.
bEffective dose was defined as the dose of antivenom capable of prolonging the clotting time of challenge dose to 3 times that of the control. ED was expressed in units of antivenom volume (µl) and venom amount per unit volume of antivenom (mg/ml).
cNormalized ED was derived from ED (mg/ml) by normalizing the antivenom volume by antivenom protein concentration.
Figure 3Efficacy of the Taiwan Daboia siamensis Monovalent Antivenom (DsMAV-Taiwan) in neutralizing the toxic effects of D. siamensis venoms from Guangxi and Taiwan. (A) Procoagulant effect; (B) Hemorrhagic effect. (C) Lethal effect.
Hemorhagic effect of Daboia siamensis venoms sourced from Guangxi and Taiwan and its neutralization by antivenoms.
| MHDa (µg/mouse) | Challenge dose (2MHD) (µg/mouse) | DsMAV-Taiwan | GbMAV | DaMAV | ||||
|---|---|---|---|---|---|---|---|---|
| ED50b (µl, mg/ml) | Normalized ED50, n-ED50c (mg/g) | ED50b (µl, mg/ml) | Normalized ED50, n-ED50c (mg/g) | ED50b (µl, mg/ml) | Normalized ED50, n-ED50c (mg/g) | |||
| Guangxi | 3.42 ± 0.12 | 6.84 | 0.871 ± 0.159, | 406.74 | >5, | <6 | >5, | <6 |
| Taiwan | 8.21 ± 0.31 | 16.42 | 0.418 ± 0.082, | 2035.35 | >5, | <6 | >5, | <6 |
MHD: Minimal hemorrhagic dose; ED50: Median effective dose.
aMinimal hemorrhagic dose was defined as the amount of venom (µg) required to induce a skin hemorrhagic lesion of 10 mm diameter.
bMedian effective dose was defined as the dose of antivenom capable of reducing the venom hemorrhagic activity of 2MHD by 50%. ED50 was expressed in units of antivenom volume (µl) and venom amount per unit volume of antivenom (mg/ml).
cNormalized ED50 was derived from ED50 (mg/ml) by normalizing the antivenom volume by its protein concentration.
Lethality of Daboia siamensis venoms sourced from Guangxi and Taiwan and the efficacy of antivenoms in neutralizing the lethal effect.
| Challenge dose | ED50 (µl)b | ER50 (mg/ml)c | Potency, P (mg/ml)d | AV protein concentration (mg/ml) | Normalized P, n-P (mg/g)e | ||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Guangxi | 5 | 0.18 (0.12–0.27) | 11.24 | 1.76 (1.17–2.64) | 1.41 | 19.3 ± 0.5 | 73.1 |
| Taiwan | 5 | 0.09 (0.06–0.14) | 4.90 | 2.02 (1.35–3.14) | 1.62 | 19.3 ± 0.5 | 83.9 |
|
| |||||||
| Guangxi | 5 | 0.18 (0.12–0.27) | 91.24 | 0.22 (0.14–0.33) | 0.17 | 168.5 ± 0.7 | 1.0 |
|
| |||||||
| Guangxi | 5 | 0.18 (0.12–0.27) | N.E. | N.E. | N.E. | 181.1 ± 6.4 | N.E. |
LD50: Median lethal dose; ED50: Median effective dose; ER50: Median effective ratio; MCD: Minimal clotting dose; ED: Effective dose; N.E.: Non-effective.
aMedian lethal dose was defined as the dose of venom (µg/ml) at which 50% of mice were dead.
bMedian effective dose was defined as the dose of antivenom (µl) at which 50% of mice survived.
cMedian effective ratio was defined as the ratio of venom (mg) to the volume dose of antivenom (ml) at which 50% of mice survived.
dPotency, P was defined as the amount of venom (mg) completely neutralized by one ml of antivenom (ml).
eNormalized P, n-P was defined as the neutralization potency of the antivenom in mg venom/g antivenom protein.